Clinical Report: FDA Clears First Eyeglass Lenses to Slow Myopia

Overview

The FDA has authorized the Essilor Stellest eyeglass lenses, the first in the U.S. designed to correct nearsightedness and slow its progression in children aged 6 to 12. Clinical data indicate a 71% reduction in myopia progression and a 53% decrease in eye elongation compared to standard lenses.

Background

Myopia, or nearsightedness, affects approximately 40% of the U.S. population, particularly in children. The condition can lead to serious ocular complications if left untreated, including retinal detachment and glaucoma. The introduction of Stellest lenses provides a new option for managing pediatric myopia, expanding beyond existing contact lens solutions.

Data Highlights

Key Findings

• Essilor Stellest lenses are the first FDA-cleared glasses to slow myopia progression in children.
• Designed for children aged 6 to 12, they correct nearsightedness while addressing its progression.
• Clinical trials showed a 71% reduction in myopia progression compared to standard lenses.
• Eye elongation was reduced by 53% with Stellest lenses.
• Reported side effects included visual disturbances such as blur and halos.
• Myopia is projected to affect over 50% of the global population by 2050.

Clinical Implications

The introduction of Stellest lenses offers healthcare professionals a new tool for managing pediatric myopia, potentially reducing the long-term risk of serious ocular conditions. Clinicians should consider these lenses as part of a comprehensive myopia management strategy for children.

Conclusion

The FDA's approval of Essilor Stellest lenses marks a significant advancement in the treatment of pediatric myopia, providing an effective option to slow its progression and improve children's visual health.

References

1. Contact Lens Spectrum, 2025 -- First Eyeglass Lenses to Slow Myopia Cleared by FDA
2. Eyecare Business, 2025 -- First Eyeglass Lenses to Slow Myopia Cleared by FDA
3. Associated Press Health, 2025 -- Essilor Stellest glasses: FDA-approved lens aim to slow myopia progression
4. FDA, 2025 -- FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia
5. Eyecare Business — 2/19 Effective Myopia Management Technology Recognized by FDA
6. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia | FDA
7. IMI—Interventions for Controlling Myopia Onset and Progression 2025